AR018166A1 - Productos utilizables en el tratamiento de tumores, una composicion farmaceutica y el uso de una antraciclina sola o con un inhibidor de topoisomerasa iantineoplasico en la preparacion de medicamentos - Google Patents

Productos utilizables en el tratamiento de tumores, una composicion farmaceutica y el uso de una antraciclina sola o con un inhibidor de topoisomerasa iantineoplasico en la preparacion de medicamentos

Info

Publication number
AR018166A1
AR018166A1 ARP990101246A ARP990101246A AR018166A1 AR 018166 A1 AR018166 A1 AR 018166A1 AR P990101246 A ARP990101246 A AR P990101246A AR P990101246 A ARP990101246 A AR P990101246A AR 018166 A1 AR018166 A1 AR 018166A1
Authority
AR
Argentina
Prior art keywords
inhibitor
preparation
topoisomerase
treatment
tumors
Prior art date
Application number
ARP990101246A
Other languages
English (en)
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of AR018166A1 publication Critical patent/AR018166A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proveen productos utilizables en el tratamiento de tumores, productos que contienen una antraciclina de formula (Ia) o (Ib) y un inhibidor detopoisomerasa I antineoplásico como un preparado combinado para uso simultaneo, individual o secuencial enel tratamiento de tumores. Asimismo se provee unacomposicion framcéutica que comprende un vehículo o un excipiente farmacéuticamente aceptable y, como ingrediente activo, la antraciclina de formula (Ia) o(Ib), y un inhibidor de topoisomerasa I antineoplásico; el uso de la antraciclina de formula (Ia) o (Ib), y un inhibidor de topoisomerasa I antineoplásico enla preparacion de un medicamento para su uso en el tratamiento de tumores; y el uso de la antraciclina de formula (Ia) en la preparacion de un medicamento parasu uso en el tratamiento de tumores cerebrales. Ejemplos de inhibidores de topoisomerasa I específicos son camptotecina, 9-aminocamptotecina, irinotecan(CPT-11), topotecan, 7-etil-10-hidroxi-camptotecina, GI 147211 o 9-nitrocamptotecina.
ARP990101246A 1998-03-24 1999-03-22 Productos utilizables en el tratamiento de tumores, una composicion farmaceutica y el uso de una antraciclina sola o con un inhibidor de topoisomerasa iantineoplasico en la preparacion de medicamentos AR018166A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9806324.1A GB9806324D0 (en) 1998-03-24 1998-03-24 Antitumour synergetic composition

Publications (1)

Publication Number Publication Date
AR018166A1 true AR018166A1 (es) 2001-10-31

Family

ID=10829188

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101246A AR018166A1 (es) 1998-03-24 1999-03-22 Productos utilizables en el tratamiento de tumores, una composicion farmaceutica y el uso de una antraciclina sola o con un inhibidor de topoisomerasa iantineoplasico en la preparacion de medicamentos

Country Status (29)

Country Link
US (1) US6403563B1 (es)
EP (1) EP1067941B1 (es)
JP (1) JP2002507571A (es)
KR (1) KR20010034619A (es)
CN (2) CN1528334A (es)
AR (1) AR018166A1 (es)
AT (1) ATE271388T1 (es)
AU (1) AU758191B2 (es)
BR (1) BR9908391A (es)
CA (1) CA2324610A1 (es)
CZ (1) CZ295368B6 (es)
DE (1) DE69918819T2 (es)
DK (1) DK1067941T3 (es)
EA (1) EA003134B1 (es)
ES (1) ES2226366T3 (es)
GB (1) GB9806324D0 (es)
HU (1) HUP0101615A3 (es)
ID (1) ID26091A (es)
IL (1) IL138035A0 (es)
MY (1) MY133016A (es)
NO (1) NO20004703D0 (es)
NZ (1) NZ507570A (es)
PL (1) PL343098A1 (es)
PT (1) PT1067941E (es)
SI (1) SI1067941T1 (es)
TW (1) TW576740B (es)
UA (1) UA63000C2 (es)
WO (1) WO1999048503A1 (es)
ZA (1) ZA992255B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6820065B1 (en) * 1998-03-18 2004-11-16 Ascom Hasler Mailing Systems Inc. System and method for management of postage meter licenses
GB9904387D0 (en) * 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
GB9916882D0 (en) * 1999-07-19 1999-09-22 Pharmacia & Upjohn Spa Antitumor synergistic composition
GB9926843D0 (en) * 1999-11-12 2000-01-12 Pharmacia & Upjohn Spa Lipid complex of alkycyclines
US6627614B1 (en) * 2002-06-05 2003-09-30 Super Gen, Inc. Sequential therapy comprising a 20(S)-camptothecin and an anthracycline
EP1985286A1 (en) * 2007-04-24 2008-10-29 Biocompatibles UK Limited Microspheres for treatment of brain tumours
US8349764B2 (en) 2007-10-31 2013-01-08 Molycorp Minerals, Llc Composition for treating a fluid
US20090107925A1 (en) * 2007-10-31 2009-04-30 Chevron U.S.A. Inc. Apparatus and process for treating an aqueous solution containing biological contaminants
US20110207760A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Sn-38 compositions
EP2582847B1 (en) 2010-06-18 2016-10-26 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
ES2588979T3 (es) 2010-08-24 2016-11-08 Dana-Farber Cancer Institute, Inc. Procedimientos para la predicción de una respuesta contra el cáncer
US9233863B2 (en) 2011-04-13 2016-01-12 Molycorp Minerals, Llc Rare earth removal of hydrated and hydroxyl species
WO2012174378A2 (en) 2011-06-17 2012-12-20 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
FI2794907T4 (fi) 2011-12-21 2023-03-27 Menetelmiä ja materiaaleja heterotsygoottisuuden menettämisen arvioimiseksi
CA3080441A1 (en) 2012-02-23 2013-09-06 The Children's Hospital Corporation Methods for predicting anti-cancer response
AU2013273466B2 (en) 2012-06-07 2018-11-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors
WO2014160080A1 (en) 2013-03-14 2014-10-02 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
EP3693475A1 (en) 2013-04-05 2020-08-12 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
CA2931181C (en) 2013-12-09 2023-01-24 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
CN106457073A (zh) 2014-03-07 2017-02-22 安全自然资源有限公司 具有杰出的砷去除性质的氧化铈(iv)
PT3180447T (pt) 2014-08-15 2020-06-18 Myriad Genetics Inc Métodos e materiais para avaliar a deficiência de recombinação homóloga
EP4141127A1 (en) 2021-08-30 2023-03-01 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Method for assessing homologous recombination deficiency in ovarian cancer cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9114549D0 (en) * 1991-07-05 1991-08-21 Erba Carlo Spa Mono and bis alkylamino-anthracyclines
GB9325417D0 (en) * 1993-12-13 1994-02-16 Erba Carlo Spa 3'- aziridino-anthracycline derivatives

Also Published As

Publication number Publication date
AU758191B2 (en) 2003-03-20
CZ295368B6 (cs) 2005-07-13
EA200000978A1 (ru) 2001-02-26
PL343098A1 (en) 2001-07-30
BR9908391A (pt) 2000-10-31
HUP0101615A3 (en) 2002-12-28
CA2324610A1 (en) 1999-09-30
NZ507570A (en) 2003-01-31
IL138035A0 (en) 2001-10-31
AU3331499A (en) 1999-10-18
ES2226366T3 (es) 2005-03-16
DK1067941T3 (da) 2004-11-29
GB9806324D0 (en) 1998-05-20
ID26091A (id) 2000-11-23
EP1067941A1 (en) 2001-01-17
US6403563B1 (en) 2002-06-11
HUP0101615A2 (hu) 2001-10-28
WO1999048503A1 (en) 1999-09-30
DE69918819D1 (de) 2004-08-26
TW576740B (en) 2004-02-21
ZA992255B (en) 1999-10-05
NO20004703L (no) 2000-09-20
CZ20003493A3 (cs) 2001-02-14
DE69918819T2 (de) 2005-08-18
NO20004703D0 (no) 2000-09-20
ATE271388T1 (de) 2004-08-15
PT1067941E (pt) 2004-12-31
EA003134B1 (ru) 2003-02-27
CN1528334A (zh) 2004-09-15
EP1067941B1 (en) 2004-07-21
KR20010034619A (ko) 2001-04-25
MY133016A (en) 2007-10-31
SI1067941T1 (en) 2005-02-28
CN1150002C (zh) 2004-05-19
CN1294516A (zh) 2001-05-09
UA63000C2 (en) 2004-01-15
JP2002507571A (ja) 2002-03-12

Similar Documents

Publication Publication Date Title
AR018166A1 (es) Productos utilizables en el tratamiento de tumores, una composicion farmaceutica y el uso de una antraciclina sola o con un inhibidor de topoisomerasa iantineoplasico en la preparacion de medicamentos
AR037592A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno
AR017979A1 (es) Formulaciones farmaceuticas de epotilonas, metodo para su preparacion y el uso de los mismos para la manufactura de un medicamento
AR025959A1 (es) DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
AR029174A1 (es) Derivados de espirooxindol, proceso para su preparacion, formulacion farmaceutica, y utilizacion de los derivados en la manufactura de medicamentos
AR006678A1 (es) Derivados de macrolidas triciclicas, una composicion farmaceutica que los contiene, uso de los mismos para preparar medicamentos y procedimientopara su preparacion
HUP0303271A2 (hu) Rapamycin felhasználása rák kezelésére alkalmas gyógyszerkészítmény elõállítására
UA84266C2 (uk) Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування
IL176449A0 (en) Generally linear effervescent oral fentanyl dosage form and methods of administering
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
AR067347A1 (es) Combinacion antihelmintica
AU3475595A (en) Novel melatonin agonist beta -carboline derivatives and analogs with a naphthalenic structure, method for their preparation and their use as drugs
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
AR030281A1 (es) Quimioterapia de combinacion
DE69923336D1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
AP2003002763A0 (en) Controlled release formulations for oral administration
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
AR008820A1 (es) Comprimido dotado de recubrimiento laminar de maleato de trimebutina, destinado ala administracion por via oral, y un procedimiento para prepararlo
ATE523200T1 (de) Kombination mit sapacitibin (2'-cyano-2'-desoxy- n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosin) und einem zytotoxischen mittel
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
AR022621A1 (es) Composicion farmaceutica que contiene desoxipeganina para el tratamiento de la dependencia de la nicotina
WO2015036463A1 (en) Topical application of vinca alkaloids for the treatment of actinic keratosis
AR050574A1 (es) Uso de un compuesto para estimulacion del crecimiento de pelo
UY26459A1 (es) 3,4-dihidroquinazolinas 5,6-disustituidas

Legal Events

Date Code Title Description
FB Suspension of granting procedure